

# Center for the Transformation of Chemistry (CTC)



Senat der  
MPC

## The Price of Green: Life Cycle Costing for Emerging Bioplastics



2045



**What role do BIOPLASTICS play in reaching the target?  
(2026-2045)**

~400 Mt



~1%

# From biomass to biopolymers: feedstocks and polymer families

## Renewable Feedstocks

- ▶ Starch & sugars
- ▶ Plant oils
- ▶ Lignocellulose
- ▶ Hemicellulose
- ▶ Waste oils
- ▶ CO<sub>2</sub> (emerging)

## Biobased Polymers

PLA

PHA

PEF

PBS(x)

PBAT

Bio-PP

Bio-PE

Bio-PA

PTT

Polyurethanes

Epoxy resins

Cellulose  
polymers

## Market Reality

- Global bioplastics capacity projected at <1% of total by 2030
- Biodegradable ≠ drop-in: different EoL pathways required
- Most polymers still at pilot/demo scale
- Strong EU policy pull but cost signals unclear

# Why Future of bioplastics are harder than it looks

## **Cost Competitiveness**

Biopolymers carry a 2–5× price premium over fossil-based counterparts. High feedstock costs, smaller production volumes, and immature process infrastructure keep gate prices uncompetitive without policy support.

## **Feedstock Volatility & Land Use**

First-generation feedstocks (corn, sugarcane) compete with food systems and face seasonal price swings. Lignocellulosic and waste-based routes are still scaling. Sustainable sourcing is a bottleneck at every TRL stage.

## **End-of-Life Complexity**

Biodegradable ≠ industrially compostable. Mixed plastic waste streams, absent sorting infrastructure, and consumer confusion undermine circularity claims. EPR frameworks are inconsistent across EU member states.

## **Innovation & Assessment Gaps**

Environmental impact methodologies have been built for fossil chemistry. Applying LCA, SSbD, or TEA to early-TRL biopolymers introduces high uncertainty, biogenic carbon accounting debates, and missing data — distorting investment signals.

# Bioplastics Landscape: TRL & Market Readiness

Selected bio-based polymers by technology readiness and production scale (2024)

Polymer	TRL (1–9)	Production (kt/yr)	Market Status (2024)
PLA	9	390	Commercial
PHA	7	60	Scale-up
PBS	7	45	Scale-up
PEF	6	5	Pilot (Avantium ~2026)
Bio-PP	5	10	Demo
PHBV	5	8	Demo
Bio-PA	8	30	Commercial (niche)
PBAT	8	70	Commercial

The financial structure of a bioplastics facility scales **non-linearly** due to the high capital intensity of fermentation, polymerization, and purification equipment..

# Why current cost methodologies cannot capture bioplastic competitiveness

## ✘ Current Approach

### Production-Gate TEA

- ▶ Stops at factory gate — ignores use-phase and EoL costs
- ▶ Uses static feedstock & energy prices (snapshot in time)
- ▶ No carbon pricing or EPR cost integration
- ▶ Cannot model scale effects or learning curves
- ▶ Misses circular revenue (recyclate credits, biorefinery co-products)
- ▶ Linear economy assumption: produce → sell → discard

## ✔ What LCC Adds

### Life Cycle Costing

- ▶ Full value chain: feedstock → conversion → use → EoL
- ▶ Dynamic cost modelling with price trajectories
- ▶ Carbon tax & EPR fee integration as cost drivers
- ▶ Scale and learning rate effects built in
- ▶ Circular revenue streams credited to system boundary
- ▶ Comparable to fossil alternatives on a system-wide basis

*The competitiveness of bioplastics cannot be evaluated at the factory gate. The full cost story only emerges over the entire life cycle.*

# Why conventional cost analysis is insufficient for bioplastics

**2-5×**

Cost premium: bio-based vs. fossil-derived polymers

**< 2%**

Global plastics production currently bio-based (2024)

→


**2030**

EU Green Deal mandates measurable circularity metrics

## Why Life Cycle Costing?

1. LCC captures costs across the full value chain — feedstock, conversion, use, and end-of-life — not just gate price.
2. Conventional TEA snapshots miss externalities, policy costs, and circular revenue streams critical for biopolymers.
3. Dynamic LCC models future carbon pricing, feedstock volatility, and scale effects — essential for investment decisions.
4. LCC provides the common currency to compare bio-based and fossil alternatives on a **system-wide basis**.

# How LCC captures value recovery, EoL burden, and EPR cost allocation



← *Circular value return (credited back to LCC system boundary)*

# Key LCC Metrics for Bioplastics

Quantitative indicators across the techno-economic and sustainability domains

**MSP**

**Minimum Selling Price**

Break-even price at zero NPV; primary commercialisation threshold (€/kg)

**CAPEX**

**Capital Expenditure**

Upfront plant, equipment, and commissioning costs; often decisive for biopolymer scale-up

**GHG/€**

**Eco-efficiency Ratio**

kg CO<sub>2</sub>e per € of value created; integrates eLCC with LCA carbon results

**NPV**

**Net Present Value**

Discounted sum of all cash flows at chosen WACC; investment viability signal

**OPEX**

**Operating Expenditure**

Feedstock, energy, labour, maintenance, and waste treatment per annum

**PMI**

**Process Mass Intensity**

Total mass input per unit product output; proxy for resource efficiency

**IRR**

**Internal Rate of Return**

Discount rate at which NPV = 0; benchmark against capital cost of equity

**MAC**

**Marginal Abatement Cost**

Cost per tonne CO<sub>2</sub> avoided vs. fossil reference; €/tCO<sub>2</sub>e signal for policy

**EROI**

**Energy Return on Investment**

Energy output divided by energy input across full lifecycle

# Metrics Focused on Emerging Bioplastics

01



## CAPEX & OPEX Decomposition

Separates capital expenditure (plant, infrastructure) from operational costs (feedstock, energy, labour). Identifies the dominant cost driver — critical for scale-up strategy.

02



## Minimum Selling Price (MSP)

The lowest price at which a plant breaks even over its lifetime at a given discount rate. The primary benchmark for comparing biopolymer competitiveness against fossil counterparts.

03



## Net Present Value (NPV)

Discounted cash flow over the investment horizon. Captures time-value of money, policy risk, and scale trajectory. Positive NPV = economically viable project at given conditions.

04




## Marginal Abatement Cost (MAC)

Cost per tonne of CO<sub>2</sub> avoided relative to the fossil reference product. Directly comparable to EU ETS carbon price — the bridge between cost competitiveness and climate policy.

# CAPEX & OPEX Comparison

Capital and operating expenditure per 50,000 tonne/year plant — bioplastic vs. fossil equivalent




Bioplastics carry 2–3× higher CAPEX owing to unproven scale. Feedstock accounts for 40–60% of PHA's OPEX — the dominant cost driver across the sector.

# Cost Structure Decomposition


## CAPEX and OPEX allocation for representative biopolymer production routes

### CAPEX Breakdown — PHA (10 kt/yr)



■ Bioreactors & fermentation ■ Downstream separation ■ Utilities & infrastructure  
■ Engineering & commissioning ■ Working capital

### OPEX Breakdown — PLA (75 kt/yr)




■ Feedstock (corn sugar/starch) ■ Energy (steam, electricity) ■ Labour & overhead  
■ Maintenance ■ Waste treatment & EoL

**Feedstock dominates OPEX for sugar-platform biopolymers; fermentation infrastructure dominates CAPEX. Both are targets for LCC optimisation via scale, feedstock diversification, and process integration.**

# Marginal Abatement Cost

€/tCO<sub>2</sub>e required for investment viability vs. current EU ETS benchmark (€85/tCO<sub>2</sub>e)



Material	MAC
PLA	€35
PEF	€68
PBS	€82
Bio-PP	€95
PHA	€145

Thank you